First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

South Africa approves Pfizer-BioNTech COVID vaccine for...

Newsdeck

Newsdeck

South Africa approves Pfizer-BioNTech COVID vaccine for emergency use

epa08955110 Syringes are prepared by Health care workers from from Region Midtjylland (Central Jutland Region) for vaccination at the local school on the remote island of Endelave in the sea of Kattegat, Denmark, 21 January 2021. Fifty residents of the Island will have their first dose of Pfizer-BioNTech vaccine on 21 January in the gym at the local school Endelaveskolen. Denmark will not receive as many vaccines as expected from Pfizer/BioNTech in the first quarter of 2021. EPA-EFE/CLAUS FISKER DENMARK OUT
By Reuters
18 Mar 2021 0

JOHANNESBURG, March 16 (Reuters) - South Africa's drugs regulator SAHPRA said on Tuesday that it had approved a "section 21" emergency use application for the COVID-19 vaccine developed by Pfizer and BioNTech.

SAHPRA added in a statement that the approval was subject to further efficacy and safety surveillance of the vaccine in the country, including monitoring its efficacy against the dominant local coronavirus variant.

South Africa is the hardest-hit country on the African continent in terms of recorded coronavirus cases and deaths, and suffered a severe second wave of infections driven by the more infectious 501Y.V2 variant, first identified late last year.

It kick-started its vaccination campaign with Johnson & Johnson’s one-dose vaccine last month in a research study targeting up to 500,000 health workers.

But it has so far administered only 150,000 doses of the Johnson & Johnson vaccine, lagging wealthier nations on other continents that have already vaccinated millions of their citizens.

The government says it has secured 20 million doses of the two-dose Pfizer-BioNTech vaccine in bilateral negotiations, with deliveries ramping up from the second quarter of the year.

It also hopes to receive 117,000 doses of the Pfizer-BioNTech vaccine before the end of the month from the COVAX Facility, the global vaccine distribution scheme co-led by the World Health Organization and partners including the Gavi vaccines alliance.

(Reporting by Alexander Winning and Wendell Roelf; Editing by Steve Orlofsky)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted